Phathom Historical Balance Sheet

PHAT Stock

USD 6.54 0.12 1.87%

Trend analysis of Phathom Pharmaceuticals balance sheet accounts such as Current Deferred Revenue of 22.1 M, Accounts Payable of 8.8 M, Cash of 243.5 M or Non Current Assets Total of 19.1 M provides information on Phathom Pharmaceuticals' total assets, liabilities, and equity, which is the actual value of Phathom Pharmaceuticals to its prevalent stockholders. By breaking down trends over time using Phathom Pharmaceuticals balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Phathom Pharmaceuticals latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Phathom Pharmaceuticals is a good buy for the upcoming year.

Phathom Pharmaceuticals Inventory

3.37 Million

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.

About Phathom Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of Phathom Pharmaceuticals at a specified time, usually calculated after every quarter, six months, or one year. Phathom Pharmaceuticals Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of Phathom Pharmaceuticals and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which Phathom currently owns. An asset can also be divided into two categories, current and non-current.

Phathom Pharmaceuticals Balance Sheet Chart

At this time, Phathom Pharmaceuticals' Property Plant And Equipment Net is comparatively stable compared to the past year. Other Assets is likely to gain to about 816.6 K in 2025, despite the fact that Total Stockholder Equity is likely to grow to (240.9 M).

Total Assets Short Long Term Debt Total Other Current Liab Total Current Liabilities

Add Fundamental

Total Assets

Total assets refers to the total amount of Phathom Pharmaceuticals assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Phathom Pharmaceuticals books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on Phathom Pharmaceuticals balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Phathom Pharmaceuticals are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Most accounts from Phathom Pharmaceuticals' balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into Phathom Pharmaceuticals current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phathom Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

For more information on how to buy Phathom Stock please use our How to Invest in Phathom Pharmaceuticals guide.At this time, Phathom Pharmaceuticals' Property Plant And Equipment Net is comparatively stable compared to the past year. Other Assets is likely to gain to about 816.6 K in 2025, despite the fact that Total Stockholder Equity is likely to grow to (240.9 M).

	2022	2023	2024	2025 (projected)
Short and Long Term Debt Total	97.1M	139.0M	501K	476.0K
Total Assets	164.8M	413.8M	378.3M	267.1M

Short Long Term Debt Total Total Assets

Phathom Pharmaceuticals balance sheet Correlations

	Total Assets	Short Long Term Debt Total	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Current Deferred Revenue	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Capital Surpluse	Other Current Assets	Other Stockholder Equity	Total Liab	Net Invested Capital	Short Long Term Debt	Total Current Assets	Net Working Capital	Short Term Debt	Other Liab	Property Plant And Equipment Net	Other Assets	Long Term Debt
Total Assets		0.59	0.63	0.79	-0.19	0.09	0.88	-0.96	-0.87	0.85	1.0	1.0	0.94	0.93	0.94	0.96	0.8	0.39	0.92	1.0	0.99	0.03	0.8	0.76	0.58	0.8
Short Long Term Debt Total	0.59		-0.06	0.19	0.1	-0.03	0.61	-0.35	-0.45	0.62	0.63	0.63	0.58	0.67	0.45	0.61	0.31	0.43	0.66	0.59	0.62	-0.05	0.67	0.79	0.35	0.45
Other Current Liab	0.63	-0.06		0.96	-0.65	-0.24	0.74	-0.75	-0.84	0.61	0.58	0.58	0.72	0.59	0.71	0.68	0.86	-0.2	0.52	0.62	0.56	0.09	0.63	0.47	0.43	0.74
Total Current Liabilities	0.79	0.19	0.96		-0.57	-0.19	0.86	-0.86	-0.91	0.8	0.76	0.76	0.84	0.73	0.8	0.82	0.91	-0.05	0.66	0.79	0.74	0.18	0.74	0.67	0.6	0.81
Total Stockholder Equity	-0.19	0.1	-0.65	-0.57		0.88	-0.35	0.22	0.6	-0.19	-0.12	-0.12	-0.41	-0.12	-0.34	-0.31	-0.73	0.82	-0.03	-0.17	-0.12	0.37	-0.49	-0.2	0.15	-0.66
Net Tangible Assets	0.09	-0.03	-0.24	-0.19	0.88		-0.1	-0.16	0.3	0.0	0.14	0.14	-0.15	0.13	-0.03	-0.04	-0.44	0.89	0.21	0.11	0.15	0.42	-0.32	-0.12	0.32	-0.43
Current Deferred Revenue	0.88	0.61	0.74	0.86	-0.35	-0.1		-0.82	-0.92	0.9	0.87	0.87	0.94	0.93	0.84	0.94	0.83	0.22	0.88	0.88	0.85	0.11	0.93	0.89	0.63	0.84
Net Debt	-0.96	-0.35	-0.75	-0.86	0.22	-0.16	-0.82		0.85	-0.78	-0.95	-0.95	-0.87	-0.85	-0.91	-0.89	-0.81	-0.34	-0.84	-0.96	-0.94	-0.09	-0.67	-0.65	-0.59	-0.73
Retained Earnings	-0.87	-0.45	-0.84	-0.91	0.6	0.3	-0.92	0.85		-0.78	-0.84	-0.84	-0.95	-0.85	-0.91	-0.93	-0.97	0.03	-0.8	-0.87	-0.84	0.15	-0.9	-0.75	-0.41	-0.94
Accounts Payable	0.85	0.62	0.61	0.8	-0.19	0.0	0.9	-0.78	-0.78		0.86	0.86	0.84	0.85	0.75	0.85	0.69	0.31	0.81	0.85	0.81	0.42	0.78	0.92	0.86	0.7
Cash	1.0	0.63	0.58	0.76	-0.12	0.14	0.87	-0.95	-0.84	0.86		1.0	0.92	0.94	0.91	0.95	0.76	0.45	0.93	1.0	1.0	0.07	0.77	0.79	0.61	0.76
Cash And Short Term Investments	1.0	0.63	0.58	0.76	-0.12	0.14	0.87	-0.95	-0.84	0.86	1.0		0.92	0.94	0.91	0.95	0.76	0.45	0.93	1.0	1.0	0.07	0.77	0.79	0.61	0.76
Common Stock Shares Outstanding	0.94	0.58	0.72	0.84	-0.41	-0.15	0.94	-0.87	-0.95	0.84	0.92	0.92		0.94	0.96	0.99	0.88	0.17	0.91	0.94	0.91	-0.08	0.94	0.77	0.49	0.94
Capital Surpluse	0.93	0.67	0.59	0.73	-0.12	0.13	0.93	-0.85	-0.85	0.85	0.94	0.94	0.94		0.92	0.97	0.71	0.45	0.99	0.94	0.93	0.03	0.88	0.81	0.58	0.78
Other Current Assets	0.94	0.45	0.71	0.8	-0.34	-0.03	0.84	-0.91	-0.91	0.75	0.91	0.91	0.96	0.92		0.96	0.84	0.22	0.91	0.94	0.92	-0.15	0.83	0.64	0.42	0.88
Other Stockholder Equity	0.96	0.61	0.68	0.82	-0.31	-0.04	0.94	-0.89	-0.93	0.85	0.95	0.95	0.99	0.97	0.96		0.84	0.28	0.95	0.96	0.94	-0.05	0.91	0.8	0.53	0.89
Total Liab	0.8	0.31	0.86	0.91	-0.73	-0.44	0.83	-0.81	-0.97	0.69	0.76	0.76	0.88	0.71	0.84	0.84		-0.21	0.64	0.79	0.75	-0.18	0.81	0.65	0.33	0.91
Net Invested Capital	0.39	0.43	-0.2	-0.05	0.82	0.89	0.22	-0.34	0.03	0.31	0.45	0.45	0.17	0.45	0.22	0.28	-0.21		0.52	0.4	0.45	0.35	0.04	0.27	0.47	-0.15
Short Long Term Debt	0.92	0.66	0.52	0.66	-0.03	0.21	0.88	-0.84	-0.8	0.81	0.93	0.93	0.91	0.99	0.91	0.95	0.64	0.52		0.93	0.92	0.02	0.83	0.75	0.56	0.74
Total Current Assets	1.0	0.59	0.62	0.79	-0.17	0.11	0.88	-0.96	-0.87	0.85	1.0	1.0	0.94	0.94	0.94	0.96	0.79	0.4	0.93		0.99	0.04	0.79	0.76	0.59	0.79
Net Working Capital	0.99	0.62	0.56	0.74	-0.12	0.15	0.85	-0.94	-0.84	0.81	1.0	1.0	0.91	0.93	0.92	0.94	0.75	0.45	0.92	0.99		0.0	0.76	0.75	0.55	0.75
Short Term Debt	0.03	-0.05	0.09	0.18	0.37	0.42	0.11	-0.09	0.15	0.42	0.07	0.07	-0.08	0.03	-0.15	-0.05	-0.18	0.35	0.02	0.04	0.0		-0.15	0.25	0.81	-0.24
Other Liab	0.8	0.67	0.63	0.74	-0.49	-0.32	0.93	-0.67	-0.9	0.78	0.77	0.77	0.94	0.88	0.83	0.91	0.81	0.04	0.83	0.79	0.76	-0.15		0.79	0.38	0.93
Property Plant And Equipment Net	0.76	0.79	0.47	0.67	-0.2	-0.12	0.89	-0.65	-0.75	0.92	0.79	0.79	0.77	0.81	0.64	0.8	0.65	0.27	0.75	0.76	0.75	0.25	0.79		0.71	0.63
Other Assets	0.58	0.35	0.43	0.6	0.15	0.32	0.63	-0.59	-0.41	0.86	0.61	0.61	0.49	0.58	0.42	0.53	0.33	0.47	0.56	0.59	0.55	0.81	0.38	0.71		0.28
Long Term Debt	0.8	0.45	0.74	0.81	-0.66	-0.43	0.84	-0.73	-0.94	0.7	0.76	0.76	0.94	0.78	0.88	0.89	0.91	-0.15	0.74	0.79	0.75	-0.24	0.93	0.63	0.28

Click cells to compare fundamentals

Phathom Pharmaceuticals Account Relationship Matchups

Phathom Pharmaceuticals balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	295.1M	189.4M	164.8M	413.8M	378.3M	267.1M
Short Long Term Debt Total	49.0M	91.3M	97.1M	139.0M	501K	476.0K
Other Current Liab	30.4M	12.8M	14.8M	7.1M	74.2M	77.9M
Total Current Liabilities	55.5M	18.9M	26.2M	38.8M	85.7M	90.0M
Total Stockholder Equity	194.3M	72.2M	(74.8M)	(72.8M)	(253.6M)	(240.9M)
Net Tangible Assets	228.0M	194.3M	72.2M	(74.8M)	(67.3M)	(64.0M)
Net Debt	(238.5M)	(91.9M)	(58.3M)	(242.4M)	(296.8M)	(281.9M)
Retained Earnings	(385.5M)	(529.4M)	(727.1M)	(928.7M)	(1.3B)	(1.2B)
Accounts Payable	16.8M	5.2M	10.0M	12.6M	10.5M	8.8M
Cash	287.5M	183.3M	155.4M	381.4M	297.3M	243.5M
Non Current Assets Total	3.7M	2.9M	4.3M	16.4M	18.2M	19.1M
Non Currrent Assets Other	384K	341K	299K	9.9M	16.1M	16.9M
Cash And Short Term Investments	287.5M	183.3M	155.4M	381.4M	297.3M	243.5M
Common Stock Shares Outstanding	33.2M	37.0M	39.1M	51.3M	63.2M	40.4M
Liabilities And Stockholders Equity	295.1M	189.4M	164.8M	413.8M	378.3M	267.1M
Non Current Liabilities Total	45.3M	98.4M	213.4M	447.8M	546.2M	573.5M
Other Current Assets	7.7M	6.5M	10.3M	13.2M	20.9M	11.1M
Other Stockholder Equity	579.8M	601.5M	652.3M	855.9M	1.0B	657.4M
Total Liab	100.8M	117.3M	239.6M	486.6M	631.9M	663.5M
Net Invested Capital	241.3M	161.8M	20.5M	65.1M	(52.2M)	(49.6M)
Total Current Assets	291.4M	186.5M	160.5M	397.4M	360.1M	259.7M
Net Working Capital	235.8M	167.6M	134.3M	358.7M	274.4M	223.4M
Short Term Debt	8.3M	974K	1.4M	726K	1.0M	1.7M
Property Plant And Equipment Net	3.4M	2.6M	3.5M	3.6M	2.1M	3.0M
Long Term Debt	39.6M	89.7M	95.3M	137.8M	201.4M	107.5M
Capital Lease Obligations	2.0M	1.7M	1.8M	1.2M	501K	476.0K
Property Plant And Equipment Gross	3.4M	2.6M	5.0M	5.7M	4.9M	4.2M
Non Current Liabilities Other	4.1M	8.7M	117.0M	309.5M	344.8M	362.0M

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for Phathom Stock Analysis

When running Phathom Pharmaceuticals' price analysis, check to measure Phathom Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Phathom Pharmaceuticals is operating at the current time. Most of Phathom Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Phathom Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Phathom Pharmaceuticals' price. Additionally, you may evaluate how the addition of Phathom Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Phathom Historical Balance Sheet

Phathom Pharmaceuticals Inventory

3.37 Million

About Phathom Balance Sheet Analysis

Phathom Pharmaceuticals Balance Sheet Chart

Total Assets

Total Current Liabilities

Phathom Pharmaceuticals balance sheet Correlations

Phathom Pharmaceuticals Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Phathom Pharmaceuticals balance sheet Accounts

Thematic Opportunities

Explore Investment Opportunities

Additional Tools for Phathom Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Total Assets
Total Current Assets	+ 1.0	Total Assets
Cash And Short Term Investments	+ 1.0	Cash
Total Current Assets	+ 1.0	Cash
Net Working Capital	+ 1.0	Cash

Total Liab	- 0.97	Retained Earnings
Total Current Assets	- 0.96	Net Debt
Net Debt	- 0.96	Total Assets
Common Stock Shares Outstanding	- 0.95	Retained Earnings
Cash And Short Term Investments	- 0.95	Net Debt
Cash	- 0.95	Net Debt